RxDoctor Payments Data

Julie Baugher, MD

Internal Medicine · Southern Pines, NCNPI 1245218999

Payments from drug & device makers

$80,774in general payments, 2019–2025

Across 378 payments — averaging $213.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$77K
  • Novo Nordisk$1K
  • Johnson & Johnson$577
  • AbbVie$344
  • Pfizer$203
  • Abbott$180
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$8,05010%
  • Speaking & faculty fees$55,07568%
  • Travel & lodging$9,56212%
  • Food & beverage$8,06010%
  • Education$270%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,774 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$226,363
Medicare patients
706
Services billed
8,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$209,788
MounjaroTirzepatide139$150,939
EliquisApixaban130$119,540
Cosentyx Sensoready (2 Pens)Secukinumab14$101,445
JardianceEmpagliflozin38$45,266
MyrbetriqMirabegron27$29,142
XareltoRivaroxaban21$22,661
RybelsusSemaglutide21$22,322
WegovySemaglutide12$15,726
FarxigaDapagliflozin Propanediol19$12,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,815
Tresiba Flextouch U-100Insulin Degludec11$6,903
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$6,826
Atorvastatin Calcium552$6,753
PremarinEstrogens, Conjugated13$6,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy, Levemir$1,346$250,387188 claims
Lilly USA, LLCMounjaro$76,880$150,939139 claims
PfizerEliquis, Premarin$203$126,287143 claims
Boehringer IngelheimJardiance$134$45,26638 claims
Astellas Pharma US IncMyrbetriq$43$29,14227 claims
Johnson & JohnsonXarelto$577$22,66121 claims
AstraZenecaFarxiga, Brilinta$180$19,08232 claims
AbbVieSynthroid$344$4,34851 claims
Sanofi-aventis U.S. LLCLantus$12$1,57812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →